{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:21:50Z","timestamp":1758759710665,"version":"3.44.0"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Primary cutaneous aspergillosis can disseminate in premature infants. Voriconazole, dosed every 12 hours, is the preferred antifungal agent. Prior studies show difficulty achieving therapeutic targets with this regimen. We report the safety and attainment of therapeutic targets with voriconazole dosed q8h with careful therapeutic drug monitoring.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Retrospective review of 4 extremely premature infants with primary cutaneous aspergillosis given voriconazole divided every 8 hours with therapeutic drug monitoring. Demographics, voriconazole administration, treatment duration, need for debridement and patient outcomes were analyzed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>All patients survived with complete healing of affected skin. Median voriconazole duration was 69.5 days (min-max 36\u201384); 69% of voriconazole troughs on intravenous therapy were within the targeted range (1\u20135 mcg\/mL). Troughs on enteral voriconazole were consistently under the targeted range. Few mild, transient adverse effects attributable to therapy were noted.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Intravenous voriconazole every 8 hours was safe and consistently met therapeutic targets. Enteral administration consistently failed to achieve therapeutic concentrations.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000004868","type":"journal-article","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T17:07:46Z","timestamp":1748538466000},"page":"955-961","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Optimizing Voriconazole Dosing in Extremely Premature Infants With Aspergillus Infections"],"prefix":"10.1097","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2426-8151","authenticated-orcid":false,"given":"Adam","family":"Lee","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Children\u2019s Hospital of Orange County, Orange"},{"name":"Department of Pediatrics, University of California, Irvine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Tuan","family":"Tran","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Children\u2019s Hospital of Orange County, Orange"},{"name":"Department of Pharmacy, Children\u2019s Hospital of Orange County, Orange, California."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasjit","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Children\u2019s Hospital of Orange County, Orange"},{"name":"Department of Pediatrics, University of California, Irvine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Arrieta","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Children\u2019s Hospital of Orange County, Orange"},{"name":"Department of Pediatrics, University of California, Irvine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,5,28]]},"reference":[{"key":"R1-20250924","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1097\/INF.0000000000001136","article-title":"Primary cutaneous aspergillosis in a preterm infant.","volume":"35","author":"Frick","year":"2015","journal-title":"Pediatr Infect Dis J"},{"key":"R2-20250924","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.ASW.0000923320.13406.01","article-title":"Management of aspergillosis in a premature neonate.","volume":"36","author":"Parham","year":"2023","journal-title":"Adv Skin Wound Care"},{"key":"R3-20250924","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/INF.0000000000002959","article-title":"Rare infant case of pulmonary aspergilloma highlighting common challenges with voriconazole dosing.","volume":"40","author":"Abo","year":"2021","journal-title":"Pediatr Infect Dis J"},{"key":"R4-20250924","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1086\/648679","article-title":"Voriconazole pharmacokinetics and pharmacodynamics in children.","volume":"50","author":"Neely","year":"2010","journal-title":"Clin Infect Dis"},{"key":"R5-20250924","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1086\/524669","article-title":"Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes.","volume":"46","author":"Pascual","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R6-20250924","doi-asserted-by":"crossref","first-page":"4782","DOI":"10.1128\/AAC.01083-10","article-title":"Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients.","volume":"55","author":"Troke","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"R7-20250924","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/phar.1631","article-title":"Pharmacokinetic and pharmacodynamic properties of oral voriconazole in patients with invasive fungal infections.","volume":"35","author":"Wang","year":"2015","journal-title":"Pharmacotherapy"},{"key":"R8-20250924","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1592\/phco.2005.25.6.893","article-title":"Intravenous voriconazole therapy in a preterm infant.","volume":"25","author":"Muldrew","year":"2005","journal-title":"Pharmacotherapy"},{"key":"R9-20250924","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/sj.jp.7211532","article-title":"Severe primary cutaneous aspergillosis refractory to amphotericin B and the successful treatment with systemic voriconazole in two premature infants with extremely low birth weight.","volume":"26","author":"Frankenbusch","year":"2006","journal-title":"J Perinatol"},{"key":"R10-20250924","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/INF.0b013e31824acc33","article-title":"Therapeutic monitoring of voriconazole in children less than 3 years of age: a case report and summary of voriconazole concentrations for 10 children.","volume":"31","author":"Doby","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"R11-20250924","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1128\/AAC.48.6.2166-2172.2004","article-title":"Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration.","volume":"48","author":"Walsh","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"R12-20250924","doi-asserted-by":"crossref","first-page":"S121","DOI":"10.1093\/cid\/ciaa1751","article-title":"EORTC\/MSGERC definitions of invasive fungal diseases: summary of activities of the intensive care unit working group.","volume":"72","author":"Bassetti","year":"2021","journal-title":"Clin Infect Dis"},{"key":"R13-20250924","doi-asserted-by":"crossref","first-page":"1403966","DOI":"10.3389\/fphar.2024.1403966","article-title":"Case report: dose-dependent interaction between dexamethasone and voriconazole in severely ill patients with non-Hodgkin\u2019s lymphoma being treated for invasive pulmonary aspergillosis.","volume":"15","author":"Huang","year":"2024","journal-title":"Front Pharmacol"},{"key":"R14-20250924","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s40264-020-01014-2","article-title":"Consensus guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury during clinical trials in adults with chronic viral hepatitis and adults with cirrhosis secondary to hepatitis B, C and nonalcoholic steatohepatitis.","volume":"44","author":"Treem","year":"2021","journal-title":"Drug Saf"},{"key":"R15-20250924","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3390\/jof4030103","article-title":"Itraconazole, Voriconazole, and posaconazole CLSI MIC distributions for wild-type and azole-resistant Aspergillus fumigatus isolates.","volume":"4","author":"Buil","year":"2018","journal-title":"J Fungi (Basel)"},{"key":"R16-20250924","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1002\/phar.1829","article-title":"An optimized voriconazole dosing strategy to achieve therapeutic serum concentrations in children younger than 2 years old.","volume":"36","author":"Zembles","year":"2016","journal-title":"Pharmacotherapy"},{"key":"R17-20250924","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1128\/AAC.01540-12","article-title":"Highly variable plasma concentrations of voriconazole in pediatric hematopoietic stem cell transplantation patients.","volume":"57","author":"Bartelink","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"R18-20250924","doi-asserted-by":"crossref","first-page":"4116","DOI":"10.1128\/AAC.00896-10","article-title":"Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children.","volume":"54","author":"Walsh","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"R19-20250924","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1128\/AAC.00751-08","article-title":"Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies.","volume":"53","author":"Karlsson","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"R20-20250924","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1056\/NEJMra035092","article-title":"Developmental pharmacology \u2013 drug disposition, action, and therapy in infants and children.","volume":"349","author":"Kearns","year":"2003","journal-title":"N Engl J Med"},{"key":"R21-20250924","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13054-015-0753-8","article-title":"Evaluation of sulfobutylether-\u03b2-cyclodextrin (SBECD) accumulation and voriconazole pharmacokinetics in critically ill patients undergoing continuous renal replacement therapy.","volume":"19","author":"Kiser","year":"2015","journal-title":"Crit Care"},{"key":"R22-20250924","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1086\/588844","article-title":"Hallucinations during voriconazole therapy.","volume":"47","author":"Zonios","year":"2008","journal-title":"Clin Inf Dis"},{"key":"R23-20250924","first-page":"3989070","article-title":"Neurologic adverse events associated with voriconazole therapy: report of two pediatric cases.","volume":"2016","author":"Demir","year":"2016","journal-title":"Case Rep Infect Dis"},{"key":"R24-20250924","doi-asserted-by":"crossref","first-page":"e2024065963","DOI":"10.1542\/peds.2024-065963","article-title":"Survival of infants born at 22 to 25 weeks\u2019 gestation receiving care in the NICU: 2020-2022.","volume":"154","author":"Edwards","year":"2024","journal-title":"Pediatrics"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000004868","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T20:01:45Z","timestamp":1758744105000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000004868"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,28]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000004868","relation":{},"ISSN":["0891-3668","1532-0987"],"issn-type":[{"type":"print","value":"0891-3668"},{"type":"electronic","value":"1532-0987"}],"subject":[],"published":{"date-parts":[[2025,5,28]]}}}